Usha Bulusu, MD
Ophthalmology · Saginaw, MINPI 1043202948
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,000 of the $30,105 with a category attached, or 69.8%. Sight Sciences, Inc. accounts for 82.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $26,225, more than ten times the $487 reported in 2019. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $111.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$25K
- Alcon$2K
- AbbVie$892
- Ocular Therapeutix, Inc.$376
- Sun Pharmaceutical Industries Inc.$329
- Glaukos Corporation$257
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$21,00070%
- Travel & lodging$1,9516%
- Food & beverage$7,13424%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 59 | $24,856 |
| Alcon | 40 | $1,674 |
| AbbVie(2 entities) | 45 | $892 |
| Ocular Therapeutix, Inc. | 20 | $376 |
| Sun Pharmaceutical Industries Inc. | 16 | $329 |
| Glaukos Corporation | 7 | $257 |
| Tarsus Pharmaceuticals, Inc. | 11 | $231 |
| Bausch & Lomb Americas Inc. | 12 | $216 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $197 |
| ANI Pharmaceuticals, Inc. | 6 | $188 |
| Aerie Pharmaceuticals, Inc. | 8 | $166 |
| Biotissue Holdings Inc. | 6 | $128 |
| NEW World Medical,inc. | 6 | $99 |
| Merz North America, Inc. | 1 | $87 |
| Novartis | 4 | $69 |
| Harrow Eye, LLC | 2 | $57 |
| Oyster Point Pharma, Inc. | 2 | $44 |
| Kala Pharmaceuticals, Inc. | 3 | $42 |
| Nova Eye, Inc. | 1 | $26 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $24 |
| Rxsight Inc | 1 | $23 |
| Lombart Brothers, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Eyepoint US, Inc. | 1 | $16 |
| Dompe US, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,105 in reported general payments places this provider in the 95th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 86 | $50,686 |
| RocklatanNetarsudil Mesylat/Latanoprost | 77 | $48,646 |
| VyzultaLatanoprostene Bunod | 69 | $34,694 |
| LumiganBimatoprost | 52 | $30,810 |
| Bromfenac Sodium | 108 | $27,876 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 64 | $23,240 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 60 | $13,456 |
| Cyclosporine | 19 | $13,246 |
| Latanoprost | 442 | $10,494 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $9,338 |
| Prednisolone Acetate | 253 | $8,746 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 295 | $8,182 |
| Brimonidine Tartrate | 150 | $7,057 |
| ProlensaBromfenac Sodium | 19 | $6,480 |
| Travoprost | 27 | $6,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $166 | $99,332163 claims |
| AbbVieLumigan, Combigan | $892 | $40,14873 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $216 | $34,69469 claims |
| AlconSimbrinza | $1,674 | $23,24064 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $197 | $8,96835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Saginaw
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
- Yannis PaulusAnn Arbor$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.